12-Month Results From Ongoing Phase 3 Fabry Disease Monotherapy Study Anticipated 3Q13 Phase 2b Pompe Co-Administration Study on Track to Begin 3Q13 CRANBURY, N.J., May 9, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the first quarter ended March 31, 2013. The Company also summarized recent and upcoming milestones and reiterated full-year 2013 operating expense guidance. Key Highlights and Upcoming Milestones:
- 12-month results from first ongoing Phase 3 Fabry monotherapy study ( Study 011) anticipated 3Q13. FDA will consider entirety of 6- and 12-month data for potential U.S. approval of migalastat HCl monotherapy.
- Phase 2b repeat-dose clinical study of AT2220 (duvoglustat HCl) co-administered with ERT (Myozyme®/Lumizyme®) for Pompe disease expected to begin 3Q13.
- IND submission for Fabry chaperone-ERT co-formulated product planned by year-end 2013 for potential entry into clinic in early 2014.
- Next-generation ERTs for Pompe disease and other LSDs advancing in preclinical studies.
Financial Highlights for First Quarter Ended March 31, 2013
- Cash, cash equivalents, and marketable securities totaled $84.8 million at March 31, 2013 compared to $99.1 million at December 31, 2012.
- Cash reimbursements received from GlaxoSmithKline (GSK) for shared development of migalastat HCl totaled $3.2 million compared to $5.0 million in the first quarter 2012.
- No revenue was reported due to a change in revenue recognition accounting under the expanded GSK collaboration. Total revenue of $7.8 million was recognized in the first quarter 2012.
- Total operating expenses decreased to $17.3 million from $18.5 million in the first quarter 2012 due to lower research and development expenses as well as a decrease in personnel-related costs.
- Net loss was $17.5 million, or $0.35 per share, compared to a net loss of $13.1 million, or $0.35 per share, for the first quarter 2012.
- Study 011 is comparing migalastat HCl to placebo to support a potential U.S. marketing application. The FDA has indicated that it will consider the entirety of the efficacy and safety data from the 6-month double-blind treatment period (Stage 1) and 6-month follow-up period (Stage 2) of Study 011. The Stage 1 results have been reported while Stage 2 data are anticipated in the third quarter of 2013. A Type C meeting with the FDA has been scheduled during the second quarter to review the statistical analysis plan. Both Amicus and GSK will remain blinded to the Stage 2 results until after this Type C meeting has occurred. Following the announcement of 12-month results, an additional meeting is anticipated with the FDA to discuss a U.S. marketing application for migalastat HCl monotherapy.
- Study 012 is comparing open-label migalastat HCl to current standard of care ERTs (Fabrazyme and Replagal) to support global registration. A total of 60 patients were randomized 1.5:1 to switch from ERT to migalastat HCl or remain on ERT. Data are anticipated in the second half of 2014 on the primary outcome measure, which is renal function assessed by iohexol Glomerular Filtration Rate (GFR) at 18 months.
The results from an open-label Phase 2 study ( Study 013) of migalastat HCl co-administered with ERT (Fabrazyme® or Replagal®) have built confidence around the concept that migalastat HCl in combination with ERT can increase levels of active enzyme in plasma and tissues and support the rationale for the first repeat-dose clinical study with the chaperone ERT co-formulated product.CHART Programs for Pompe Disease Outside the collaboration agreement with GSK, Amicus owns exclusive rights to the rest of its pipeline and applications of its CHART platform technology. The current CHART programs for Pompe disease are investigating the pharmacological chaperone AT2220 in combination with human recombinant GAA (rhGAA) enzymes. These next-generation therapies have the potential to increase enzyme activity in muscle and other disease-relevant tissues, improve glycogen reduction, and mitigate immunogenicity compared to rhGAA alone.
- AT2220-IV Co-Administered with Marketed ERTs : Amicus plans to initiate a repeat-dose Phase 2b clinical study in the third quarter of 2013 to evaluate a novel intravenous formulation of AT2220 (AT2220-IV) co-administered with currently marketed rhGAA (Myozyme/Lumizyme) in Pompe patients.To build upon positive results from a Phase 2 co-administration study ( Study 010),Amicus plans to evaluate AT2220-IV co-administered with Myozyme/Lumizyme every 2 weeks to characterize safety, PK, and anti-rhGAA antibody titers. The study is expected to include both treatment-naïve and ERT-experienced individuals at leading Pompe centers.
- Next-Generation ERT (AT2220 Co-Formulated with a Proprietary rhGAA Enzyme): Amicus is also developing a proprietary rhGAA enzyme co-formulated with AT2220 as a next-generation therapy for Pompe disease. Amicus believes it has the potential to improve the properties of the rhGAA enzyme itself while incorporating AT2220 as a small molecule stabilizer to increase exposure and tissue uptake of active enzyme, reduce immunogenicity and potentially enable novel routes of delivery such as subcutaneous administration.
An audio/visual webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://www.amicusrx.com , and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.The slide presentation for today's conference call and webcast is also available in the Investors section of the Amicus Therapeutics corporate web site at http://www.amicusrx.com . A telephonic replay of the call will be available for seven days beginning at 8:00 p.m. ET today. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 64638686. About Amicus Therapeutics Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease. About Chaperone-Advanced Replacement Therapy (CHART) The Chaperone-Advanced Replacement Therapy (CHART™) platform combines unique pharmacological chaperones with enzyme replacement therapies (ERTs) for lysosomal storage diseases (LSDs). In a chaperone-advanced replacement therapy, a unique pharmacological chaperone is designed to bind to and stabilize a specific therapeutic enzyme in its properly folded and active form. This proposed CHART mechanism may allow for enhanced tissue uptake of active enzyme, greater lysosomal activity, more reduction of substrate, and lower immunogenicity compared to ERT alone. Improvements in enzyme stability may also enable more convenient delivery of next-generation therapies. Amicus is leveraging the CHART platform to develop pharmacological chaperones co-administered with currently marketed ERTs as well as proprietary next-generation therapies that consist of lysosomal enzymes co-formulated with pharmacological chaperones.
About Migalastat HCl for Fabry DiseaseMigalastat HCl is an investigational pharmacological chaperone in development as a monotherapy and in combination with enzyme replacement therapy (ERT) for the treatment of Fabry disease. As a monotherapy, migalastat HCl is designed to bind to and stabilize, or "chaperone" a patient's own alpha-galactosidase A (alpha-Gal A) enzyme in those with genetic mutations that are amenable to this chaperone in a cell-based assay. For patients currently receiving ERT for Fabry disease, migalastat HCl in combination with ERT may improve ERT outcomes by keeping the infused alpha-Gal A enzyme in its properly folded and active form. Fabry disease is an inherited lysosomal storage disorder caused by deficiency of the alpha-Gal A enzyme. The role of alpha-Gal A within the body is to break down specific lipids in lysosomes, including globotriaosylceramide (GL-3, also known as Gb3). Lipids that can be degraded by the action of alpha-Gal A are called "substrates" of the enzyme. Reduced or absent levels of alpha-Gal A activity leads to the accumulation of GL-3 in the affected tissues, including the kidneys, heart, central nervous system, and skin. This accumulation of GL-3 is believed to cause the various manifestations of Fabry disease, including pain, kidney failure, and increased risk of heart attack and stroke. It is currently estimated that Fabry disease affects approximately 5,000 to 10,000 people worldwide. However, several literature reports suggest that Fabry disease may be significantly under-diagnosed, and the prevalence of the disease may be much higher. About CHART for Pompe Disease In chaperone-advanced replacement therapy programs for Pompe disease, the small molecule pharmacological chaperone AT2220 is designed to bind to and stabilize human recombinant GAA (rhGAA) enzyme. Amicus is developing AT2220 co-administered with currently marketed ERTs (rhGAA enzymes, Myozyme/Lumizyme) in parallel with the development of a next-generation ERT (AT2220 co-formulated with a proprietary rhGAA enzyme). Positive results from a Phase 2 study ( Study 010) established human proof-of-concept that oral administration of AT2220 just prior to infusing Myozyme/Lumizyme increases enzyme activity in muscle compared to ERT alone. In preclinical studies of AT2220 co-administered and co-formulated with Myozyme/Lumizyme, greater enzyme uptake in disease-relevant tissues led to greater glycogen reduction compared to Myozyme/Lumizyme alone. These chaperone-advanced replacement therapies also have the potential to mitigate Pompe ERT-related immunogenicity because properly folded proteins are generally less prone to aggregation and less immunogenic. Pompe disease is a lysosomal storage disease characterized by progressive skeletal muscle weakness and respiratory insufficiency. It is caused by a deficiency in GAA activity, which leads to accumulation of glycogen in the heart, muscle, and other tissues affected by the disease. Pompe disease affects an estimated 5,000 to 10,000 individuals worldwide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression.
Forward-Looking StatementsThis press release contains, and the accompanying conference call will contain, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, and the projected cash position for the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "potential," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
|Amicus Therapeutics, Inc.|
|(a development stage company)|
|Consolidated Statements of Operations|
|(In thousands, except share and per share amounts)|
|Period from February 4, 2002|
|Ended March 31,||March 31,|
|Research revenue||$ 6,114||$ --||$ 57,493|
|Collaboration and milestone revenue||1,660||--||64,382|
|Research and development||14,004||11,989||327,882|
|General and administrative||4,095||4,823||137,436|
|Impairment of leasehold improvements||--||--||1,030|
|Depreciation and amortization||420||439||12,207|
|In-process research and development||--||--||418|
|Total operating expenses||18,519||17,251||480,495|
|Loss from operations||(10,745)||(17,251)||(358,620)|
|Other income (expenses):|
|Change in fair value of warrant liability||(2,376)||(262)||1,291|
|Loss before tax benefit||(13,137)||(17,458)||(345,055)|
|Benefit from income taxes||--||--||8,708|
|Preferred stock accretion||--||--||(802)|
|Net loss attributable to common stockholders||$ (13,137)||$ (17,458)||$ (356,573)|
|Net loss attributable to common stockholders per common share – basic and diluted||$ (0.35)||$ (0.35)|
|Weighted-average common shares outstanding – basic and diluted||37,887,520||49,621,188|
|Amicus Therapeutics, Inc.|
|(a development stage company)|
|Consolidated Balance Sheets|
|(in thousands, except share and per share amounts)|
|December 31,||March 31,|
|Cash and cash equivalents||$33,971||$26,736|
|Investments in marketable securities||65,151||58,015|
|Receivable due from GSK||3,225||1,308|
|Prepaid expenses and other current assets||2,270||1,753|
|Total current assets||104,617||87,812|
|Property and equipment, less accumulated depreciation and amortization of $8,501 and $8,872 at December 31, 2012 and March 31, 2013, respectively||5,029||4,962|
|Other non-current assets||442||442|
|Liabilities and Stockholders' Equity|
|Accounts payable and accrued expenses||8,845||6,427|
|Current portion of secured loan||398||398|
|Total current liabilities||9,243||7,995|
|Warrant liability, non-current||908||--|
|Secured loan, less current portion||299||199|
|Commitments and contingencies|
|Common stock, $.01 par value, 125,000,000 shares authorized, 49,631,672 shares issued and outstanding at December 31, 2012, 49,631,672 shares issued and outstanding at March 31, 2013||556||556|
|Additional paid-in capital||387,539||389,113|
|Accumulated other comprehensive income||14||15|
|Deficit accumulated during the development stage||(318,889)||(336,347)|
|Total stockholders' equity||69,220||53,337|
|Total Liabilities and Stockholders' Equity||$110,088||$93,216|
CONTACT: Investors/Media: Sara Pellegrino firstname.lastname@example.org (609) 662-5044